DuPont's Strong Q4 Results Sets The Stage For 2026

DuPont’s latest update gave investors something rare and refreshing in any market climate - clear numbers and confident guidance. In its fourth-quarter and full-year 2025 update, the company said 2025 net sales were up 2% at $6.849 billion, adjusted EPS was $1.68, and transaction-adjusted free cash flow was $689 million — all while management emphasized execution and cash generation.

For 2026, DuPont guidance has net sales at $7.075–$7.135 billion, operating EBITDA of $1.725–$1.755 billion, and adjusted EPS of $2.25–$2.30. For the first quarter, it guided to $1.67 billion in net sales and $0.48 adjusted EPS. CFO Antonella Franzen stated, "Our 2026 guidance is in line with the medium-term targets communicated at our recent investor day. Our full year net sales guidance assumes about 3% organic growth and a currency tailwind of about 1% versus last year."

The underlying “what’s working” story in 2025 leaned heavily toward DuPont’s Healthcare & Water Technologies segment, where the company reported 7% organic sales growth for the year. It attributed strength to areas like medical packaging, biopharma, and water markets. Meanwhile, Diversified Industrials posted a 2% decline in organic sales, with DuPont pointing to ongoing construction market weakness as a drag — so, not everything was a victory lap, but the portfolio mix is doing some of the heavy lifting.

DuPont’s guidance ranges set a confident tone for 2026, and the company positioned Healthcare & Water Technologies as a key engine as it works through weaker conditions in construction-linked end markets. Now the near-term focus is whether DuPont can deliver on the mix of growth, margins, and cash generation embedded in its outlook — and whether the segment momentum it highlighted in 2025 carries into 2026 as the economic backdrop evolves.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726